Health-Holland

Venture financing of biotech companies Source: The Dutch Life Sciences Trend Analysis 2018 Financing value Number of rounds Financing value (Million USD) Number of Rounds 2013 H1 104.7 11 140.0 120.0 100.0 80.0 60.0 40.0 20.0 0.0 15 10 5 0 2013 H2 85.8 9 2014 H1 110.7 8 2014 H2 60.9 10 2015 H1 4.3 2 2015 H2 121.1 10 2016 H1 65.5 14 2016 H2 14.8 6 2017 H1 24.0 5 2017 H2 39.1 7 Financing Value – Number of rounds “The Netherlands has many promising start-ups in the pharma sector, such as Acerta Pharma. The potential of the technology of Acerta Pharma and the quality of its scientists were reasons for our interest in this company. We did a majority share investment in the company in 2016. Since then, Acerta Pharma serves as the Hematologic Oncology Center of Excellence of our company, working on several new targeted therapies for patients with hematologic malignancies.” Patrick Connor , Country President Netherlands at AstraZeneca 22